Clopidogrel Bisulfate
Product Images NDC 63629-8045

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 63629-8045). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

4ec4203e F1f8 0398 E054 00144ff88e88

4ec4203e F1f8 0398 E054 00144ff88e88
Two round, pink tablets of Clopidogrel bisulfate from Bryant Ranch Prepack. One tablet is imprinted with 'SG', and the other with '124'. No strength or dosage information is visible on the tablets.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A horizontal error bar chart showing the effect of co-administered proton pump inhibitors (PPIs) on exposure to clopidogrel active metabolite. The chart compares multiple doses of clopidogrel 75 mg alone versus with PPIs including Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg. The x-axis represents change relative to clopidogrel administered alone, ranging from 0.4 to 1.4, with confidence intervals shown for each PPI.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A line graph titled 'Cardiovascular Death, Myocardial Infarction, Stroke in the CURE Study' showing cumulative event rate (%) over 12 months of follow-up. The graph compares two groups: placebo (+ aspirin) and clopidogrel (+ aspirin). The placebo group shows a higher cumulative event rate than the clopidogrel group, with a p-value of 0.00009. A footnote indicates other standard therapies were used as appropriate.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A hazard ratio forest plot chart depicting patient baseline characteristics and on-study concomitant medications/interventions for the CURE study. The chart compares Clopidogrel and placebo groups across multiple subgroups such as age, gender, race, diabetes, previous MI, and various medications, displaying hazard ratios with 95% confidence intervals favoring either Clopidogrel or placebo along a horizontal axis.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A Kaplan-Meier survival curve chart showing the percentage of deaths before first discharge over 28 days since randomization. It compares two groups: Placebo and Clopidogrel. The placebo group shows 1845 deaths (8.1%) and the Clopidogrel group shows 1726 deaths (7.5%), indicating a 7% proportional risk reduction with Clopidogrel (p=0.03).*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
A line graph depicting the percentage of patients with death, re-infarction, or stroke before first discharge over up to 28 days since randomization. It compares placebo versus clopidogrel groups, showing fewer events in the clopidogrel group with a 9% proportional risk reduction (p=0.002).*
FDA Label Image

Figure 6 (Figure 6)

Figure 6 (Figure 6)
A clinical efficacy forest plot showing odds ratios with 99% confidence intervals for Clopidogrel bisulfate versus placebo across various subgroups including gender, age at entry, hours since onset, systolic blood pressure (SBP), heart rate, and fibrinolytic agent given. Each subgroup lists sample sizes and event counts for Clopidogrel and placebo and visually compares the favorability between treatments.*
FDA Label Image

Figure 7 (Figure 7)

Figure 7 (Figure 7)
A line graph titled 'Fatal or Non-Fatal Vascular Events' showing the cumulative event rate (%) on the Y-axis and months of follow-up on the X-axis, up to 36 months. Two lines represent event rates for Aspirin and Clopidogrel, with Clopidogrel generally showing a lower cumulative event rate. A p-value of 0.045 is noted on the graph.*
FDA Label Image

Figure 8 (Figure 8)

Figure 8 (Figure 8)
A forest plot showing hazard ratios with 95% confidence intervals comparing Clopidogrel and Aspirin across qualifying conditions: stroke, myocardial infarction (MI), and peripheral artery disease (PAD), as well as overall. The plot displays the number and percentage of events for each treatment group per condition and visually indicates which treatment is favored based on hazard ratios, ranging from 0.6 to 1.3 on the x-axis.*
FDA Label Image

Structural Formula (Structural Formula)

Structural Formula (Structural Formula)
Chemical structure of clopidogrel bisulfate showing the bicyclic thienopyridine core, an acetate ester group, a chlorine-substituted phenyl ring, and the bisulfate salt component (H2SO4).*
FDA Label Image

Label Image (Lbl636298045)

Label Image (Lbl636298045)
Label for Clopidogrel bisulfate 75 mg tablets by Bryant Ranch Prepack. The label includes a note to compare to Plavix 75 mg tablet by ScieGen Pharmaceuticals Inc. It indicates a quantity of 90 tablets, pink round shape, and storage instructions at 20-25°C (68-77°F). Contains NDC 63629-8045 and barcode present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.